Published On : 23 june 2025
• The global stented biological valve market size was valued at USD 2.76 billion in 2024. The market is projected to grow from USD 2.94 billion in 2025 to USD 4.25 billion by 2032, exhibiting a CAGR of 6.4% during the forecast period.
Email: help@intelmarketresearch.com +91 9169164321
• Stented biological valves are bioprosthetic heart valves made from animal tissues (bovine or porcine) with an integrated metallic or polymeric stent structure. These valves are primarily used in patients requiring valve replacement who cannot tolerate long-term anticoagulation therapy. The stent provides structural support, facilitating precise implantation during surgical or transcatheter procedures. The global stented biological valve market is experiencing significant growth, driven by the increasing prevalence of valvular heart diseases, advancements in surgical techniques, and a rising geriatric population. Stented tissue valves, which include bovine and porcine valves, are widely utilized in heart valve replacement procedures due to their durability and compatibility with the human body. These valves are supported by a metal or polymer frame (stent) that helps in maintaining the valve's shape and facilitating its placement. According to the United Nation Department of Economic and Social Affairs, In 2020, there are an estimated 727 million persons aged 65 years or over worldwide. This number is projected to more than double by 2050, reaching over 1.5 billion persons
•Hospital •Clinic •Ambulatory Surgical Centers (ASCs)
•Other
Bovine pericardial tissue
Porcine tissue
Synthetic materials
Email: help@intelmarketresearch.com +91 9169164321 Key Players :
• Edwards Lifesciences Corporation (U.S.)
• St. Jude Medical (Abbott) (U.S.)
• Meril Life Sciences (India)
• Boston Scientific Corporation (U.S.)
• Laboratoires Cryolife (France)
• Abbott Laboratories (U.S.)
